Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18006575 | 0.92 | PLA2G2A (0.39) | PLA2G2ACYP3A4GAAPLA2G4ALAP3 | |
| SCHEMBL269622 | 0.87 | CYP3A4 (0.38) | CYP3A4GAAANPEPLAP3ERAP1 | |
| SCHEMBL11758345 | 0.85 | CYP3A4 (0.37) | CYP3A4GAAANPEPLAP3ERAP1 | |
| SCHEMBL1396965 | 0.85 | CYP3A4 (0.37) | CYP3A4GAAANPEPLAP3ERAP1 | |
| SCHEMBL11142547 | 0.83 | BTN3A1 (0.38) | CYP3A4GAAANPEPLAP3ERAP1 | |
| SCHEMBL13112850 | 0.81 | PLA2G2A (0.42) | PLA2G2APLA2G4A | |
| SCHEMBL25788449 | 0.81 | PLA2G2A (0.42) | PLA2G2A | |
| SCHEMBL15783767 | 0.80 | PLA2G2A (0.43) | PLA2G2APLA2G4ALAP3 | |
| SCHEMBL28543424 | 0.80 | PLA2G2A (0.40) | PLA2G2APLA2G4A | |
| SCHEMBL3951836 | 0.79 | BTN3A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-01-26 | — | — | US | disclosed |
| CN-109485676-A | Novel nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2019-03-19 | — | — | CN | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-0018415-B1 | PROCESS FOR PRODUCING ALKYL 4-(ALKOXY METHYL PHOSPHINOYL)BUTYRATES AND ALKYL-(2-AMINO-4-(ALKOXY METHYL PHOSPHINOYL)) BUTYRATES | MEIJI SEIKA KAISHA LTD. (JP) | 1982-10-13 | — | — | EP | disclosed |
| EP-0018415-A1 | Process for producing alkyl 4-(alkoxy methyl phosphinoyl)butyrates and alkyl-(2-amino-4-(alkoxy methyl phosphinoyl)) butyrates | MEIJI SEIKA KAISHA LTD. (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | PLA2G2A 1979/4885CYP3A4 477/4885GAA 1404/4885 |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | PLA2G2A 1878/4885CYP3A4 783/4885GAA 228/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | PLA2G2A 1878/4885CYP3A4 783/4885GAA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.